Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia.
Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Am J Transplant. 2019 Dec;19(12):3367-3376. doi: 10.1111/ajt.15472. Epub 2019 Jul 1.
Preemptive kidney transplantation is the preferred initial renal replacement therapy, by avoiding dialysis and reportedly maximizing patient survival. Lead time bias may account for some or all of the observed survival advantage, but the impact of this has not been quantified. Using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, we included adult recipients of living donor kidney transplants during 1998-2017. Patients were transplanted preemptively (n = 1435) or after receiving up to 6 months of dialysis (n = 712). We created a matched cohort using propensity scores, and accounted for lead time (dialysis and estimated predialysis) using left-truncated Cox models with the primary outcome of patient survival. The median eGFR at transplantation was 6.9 mL/min per 1.73 m in the non-pre-emptive, and 9.6 mL/min per 1.73 m in the preemptive group. In the matched cohort (n = 1398), preemptive transplantation was not associated with a survival advantage hazard ratio (HR) for preemptive vs non-pre-emptive 1.12 (95% confidence interval [CI] 0.79-1.61). Accounting for lead time moved the point estimates toward a survival disadvantage for preemptive transplantation (eg, HR assuming 4 mL/min per 1.73 m /year eGFR decline, 1.21 [0.85, 1.73]), but in all cases the 95% CIs crossed 1. The optimal timing of preemptive living donor kidney transplantation requires further study.
抢先进行肾移植是首选的初始肾脏替代治疗方法,可以避免透析,并据报道最大限度地提高患者生存率。领先时间偏倚可能解释了部分或全部观察到的生存优势,但这种影响尚未量化。我们使用澳大利亚和新西兰透析和移植(ANZDATA)登记处,纳入了 1998 年至 2017 年期间接受活体供肾移植的成年受者。患者抢先(n=1435)或在接受长达 6 个月的透析后进行移植(n=712)。我们使用倾向评分创建了匹配队列,并使用左截断 Cox 模型考虑了领先时间(透析和估计的透析前),主要结局为患者生存。非抢先移植组的中位 eGFR 为 6.9 mL/min/1.73 m,抢先移植组为 9.6 mL/min/1.73 m。在匹配队列(n=1398)中,抢先移植与生存优势无关,抢先移植与非抢先移植的风险比(HR)为 1.12(95%置信区间 [CI] 0.79-1.61)。考虑到领先时间,抢先移植的点估计值向生存劣势移动(例如,假设 eGFR 每年下降 4 mL/min/1.73 m,HR 为 1.21 [0.85, 1.73]),但在所有情况下,95%CI 均未超过 1。抢先进行活体供肾移植的最佳时机需要进一步研究。